ErVaccine Technologies announces an endorsement from BPI (French Deeptech support) for a non-dilutive funding in the form of grants and repayable advances, for a total amount above 1.9 million€ on a global 24-month project of 4million€. This innovation program will bring ErVaccine cancer vaccine candidate from a pre-clinical stage to the safety demonstration in human by conducting non regulatory and regulatory pre-clinical study and CMC activities in several indications. This funding also supports the dose-escalation phase I part of a Phase I/II clinical trial in advanced metastatic Triple Negative Breast Cancer.
We are eager to kick off !